{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:11:50Z","timestamp":1787062310004,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>There are various therapeutic modalities of treatment for non-Hodgkin's lymphoma, but with certain limitations, hence, investigating the scope of combined therapeutic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      In this article, cellular toxicity, apoptosis and expression of mitogen-activated protein kinase signaling pathway proteins were investigated in Raji cells preincubated with doxorubicin followed by\n                      <jats:sup>131<\/jats:sup>\n                      I-rituximab (rituximab radiolabeled with Iodine-131) treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      It was found that the\n                      <jats:sup>131<\/jats:sup>\n                      I-rituximab in combination with doxorubicin showed a higher amount of cell toxicity and apoptosis compared to respective controls. Expression of anti-apoptotic protein (B-cell lymphoma-extra-large) was downregulated and cleavage of poly (ADP-ribose) polymerase, a marker of apoptosis was higher in cells treated with doxorubicin (2 \u03bcg\/mL) and\n                      <jats:sup>131<\/jats:sup>\n                      I-rituximab (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2264 0.05). Moreover, in these cells the basal level of expression of p42\/44 and p38 were increased while its phosphorylation was decreased.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      These results suggest that doxorubicin has the potential to sensitize\n                      <jats:sup>131<\/jats:sup>\n                      I-rituximab induced cell death in Raji cells.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.140844","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T00:48:49Z","timestamp":1455842929000},"page":"823-829","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Doxorubicin enhances 131I-rituximab induced cell death in Raji cells"],"prefix":"10.4103","volume":"11","author":[{"given":"C.","family":"Kumar","sequence":"first","affiliation":[{"name":"Isotope Applications and Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. N.","family":"Pandey","sequence":"additional","affiliation":[{"name":"Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Samuel","sequence":"additional","affiliation":[{"name":"Isotope Applications and Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Venkatesh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Sciences and Nuclear Applications, IAEA, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0889-8588(18)30390-3","article-title":"Immunologic markers in non-Hodgkin's lymphoma","volume":"5","author":"Freedman","year":"1991","journal-title":"Hematol Oncol Clin North Am"},{"key":"R2-20260109","first-page":"433","article-title":"Trends in the incidence of non-Hodgkin's lymphoma in India","volume":"9","author":"Yeole","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.nucmedbio.2011.10.020","article-title":"Combined-modality radioimmunotherapy: Synergistic effect of paclitaxel and additive effect of bevacizumab","volume":"39","author":"Jang","year":"2012","journal-title":"Nucl Med Biol"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: The good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr Med Chem"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1535-7163.MCT-06-0190","article-title":"The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays","volume":"5","author":"Smith","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: Historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/mabs.2.1.10789","article-title":"Evolution of anti-CD20 monoclonal antibody therapeutics in oncology","volume":"2","author":"Oflazoglu","year":"2010","journal-title":"MAbs"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","article-title":"Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation","volume":"63","author":"Anderson","year":"1984","journal-title":"Blood"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1158\/1078-0432.CCR-07-1255","article-title":"Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression","volume":"14","author":"Olejniczak","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus CHOP (R-CHOP) overcomes bcl-2 - associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"key":"R15-20260109","first-page":"5137","article-title":"Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine\/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs","volume":"61","author":"Alas","year":"2001","journal-title":"Cancer Res"},{"key":"R16-20260109","first-page":"836","article-title":"Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma","volume":"8","author":"Alas","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R17-20260109","first-page":"621","article-title":"Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine","volume":"17","author":"Emmanouilides","year":"2002","journal-title":"Cancer Biother Radiopharm"},{"key":"R18-20260109","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica"},{"key":"R19-20260109","first-page":"1183","article-title":"Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis","volume":"2","author":"Jazirehi","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","article-title":"Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa} B signaling pathway in non-Hodgkin's lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis","volume":"65","author":"Jazirehi","year":"2005","journal-title":"Cancer Res"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi","year":"2005","journal-title":"Oncogene"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1269\/jrr.47.183","article-title":"Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and-independent mechanisms","volume":"47","author":"Skvortsova","year":"2006","journal-title":"J Radiat Res"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00411-009-0237-9","article-title":"Rituximab sensitizes a Burkitt lymphoma cell line to cell killing by X-irradiation","volume":"48","author":"Fengling","year":"2009","journal-title":"Radiat Environ Biophys"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3121\/cmr.3.3.157","article-title":"Radioimmunotherapy for Non-Hodgkin's Lymphoma","volume":"3","author":"Rao","year":"2005","journal-title":"Clin Med Res"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1200\/JCO.2005.05.3470","article-title":"Multicenter phase II clinical study of 131 I-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma","volume":"24","author":"Leahy","year":"2006","journal-title":"J Clin Oncol"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2010-02-269753","article-title":"Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131 I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients","volume":"117","author":"Leahy","year":"2011","journal-title":"Blood"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1615\/JEnvironPatholToxicolOncol.2013006843","article-title":"Cellular internalization and mechanism of cytotoxicity of 131 I-rituximab in Raji cells","volume":"32","author":"Kumar","year":"2013","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/18744710113069990021","article-title":"Cellular toxicity and apoptosis studies in osteocarcinoma cells, a comparison of177 Lu-EDTMP and Lu-EDTMP","volume":"6","author":"Kumar","year":"2013","journal-title":"Curr Radiopharm"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2694","article-title":"Signal integration by JNK and p38 MAPK pathways in cancer development","volume":"9","author":"Wagner","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1126\/science.1072682","article-title":"Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases","volume":"298","author":"Johnson","year":"2002","journal-title":"Science"},{"key":"R31-20260109","first-page":"7170","article-title":"Anti-CD20-and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways","volume":"60","author":"Mathas","year":"2000","journal-title":"Cancer Res"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism","volume":"99","author":"Pedersen","year":"2002","journal-title":"Blood"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1038\/sj.onc.1208954","article-title":"Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis","volume":"24","author":"Vega","year":"2005","journal-title":"Oncogene"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1038\/sj.onc.1207336","article-title":"Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance","volume":"23","author":"Vega","year":"2004","journal-title":"Oncogene"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:02:45Z","timestamp":1786647765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.140844","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}